These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 34348953

  • 1. Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study.
    Hoogendoorn M, Corro Ramos I, Soulard S, Cook J, Soini E, Paulsson E, Rutten-van Mölken M.
    BMJ Open; 2021 Aug 04; 11(8):e049675. PubMed ID: 34348953
    [Abstract] [Full Text] [Related]

  • 2. Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results.
    Hoogendoorn M, Corro Ramos I, Baldwin M, Luciani L, Fabron C, Detournay B, Rutten-van Mölken MPMH.
    Int J Chron Obstruct Pulmon Dis; 2019 Aug 04; 14():447-456. PubMed ID: 30863045
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database.
    Quint JK, Montonen J, Esposito DB, He X, Koerner L, Wallace L, de la Hoz A, Miravitlles M.
    Adv Ther; 2021 May 04; 38(5):2249-2270. PubMed ID: 33721209
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
    van Boven JF, Kocks JW, Postma MJ.
    Int J Chron Obstruct Pulmon Dis; 2016 May 04; 11():2191-2201. PubMed ID: 27703341
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials.
    Buhl R, de la Hoz A, Xue W, Singh D, Ferguson GT.
    Adv Ther; 2020 Oct 04; 37(10):4175-4189. PubMed ID: 32671684
    [Abstract] [Full Text] [Related]

  • 6. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA, Cates CJ.
    Cochrane Database Syst Rev; 2015 Oct 22; (10):CD008989. PubMed ID: 26490945
    [Abstract] [Full Text] [Related]

  • 7. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
    Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, Ternouth A, Miravitlles M, Rutten-van Mölken M, Goosens LM, Buyukkaramikli N, Acciai V.
    Ther Adv Respir Dis; 2016 Oct 22; 10(5):391-401. PubMed ID: 27405723
    [Abstract] [Full Text] [Related]

  • 8. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO® and OTEMTO® Studies.
    Buhl R, Singh D, de la Hoz A, Xue W, Ferguson GT.
    Adv Ther; 2020 Aug 22; 37(8):3485-3499. PubMed ID: 32462607
    [Abstract] [Full Text] [Related]

  • 9. COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy.
    Calverley PMA, Hoz A, Xue W, Ferguson GT, Miravitlles M.
    COPD; 2020 Oct 22; 17(5):477-484. PubMed ID: 32928003
    [Abstract] [Full Text] [Related]

  • 10. Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials.
    Rabe KF, Chalmers JD, Miravitlles M, Kocks JWH, Tsiligianni I, de la Hoz A, Xue W, Singh D, Ferguson GT, Wedzicha J.
    Adv Ther; 2021 Jan 22; 38(1):579-593. PubMed ID: 33175291
    [Abstract] [Full Text] [Related]

  • 11. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.
    Chong J, Karner C, Poole P.
    Cochrane Database Syst Rev; 2012 Sep 12; 2012(9):CD009157. PubMed ID: 22972134
    [Abstract] [Full Text] [Related]

  • 12. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.
    Singh D, Gaga M, Schmidt O, Bjermer L, Grönke L, Voß F, Ferguson GT.
    Respir Res; 2016 Jun 18; 17(1):73. PubMed ID: 27316465
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
    Ferguson GT, Darken P, Ballal S, Siddiqui MK, Singh B, Attri S, Holmgren U, de Nigris E.
    Adv Ther; 2020 Jun 18; 37(6):2956-2975. PubMed ID: 32335859
    [Abstract] [Full Text] [Related]

  • 14. Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score-matched cohort analysis.
    Muro S, Suzuki M, Nakamura S, Wang JR, Garry EM, Sakamoto W, de Souza S.
    Respir Res; 2021 Jun 17; 22(1):180. PubMed ID: 34140019
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
    Ferguson GT, Fležar M, Korn S, Korducki L, Grönke L, Abrahams R, Buhl R.
    Adv Ther; 2015 Jun 17; 32(6):523-36. PubMed ID: 26112656
    [Abstract] [Full Text] [Related]

  • 16. Combination inhaled steroid and long-acting beta₂-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease.
    Rojas-Reyes MX, García Morales OM, Dennis RJ, Karner C.
    Cochrane Database Syst Rev; 2016 Jun 06; 2016(6):CD008532. PubMed ID: 27271056
    [Abstract] [Full Text] [Related]

  • 17. A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol.
    Buhl R, Dreher M, Korn S, Taube C, Stock C, Zehendner CM, Kondla A, Vogelmeier CF.
    Int J Chron Obstruct Pulmon Dis; 2020 Jun 06; 15():2601-2608. PubMed ID: 33122898
    [Abstract] [Full Text] [Related]

  • 18. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
    Ramadan WH, Kabbara WK, El Khoury GM, Al Assir SA.
    Int J Chron Obstruct Pulmon Dis; 2015 Jun 06; 10():2347-56. PubMed ID: 26586940
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
    Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K.
    Int J Chron Obstruct Pulmon Dis; 2012 Jun 06; 7():183-99. PubMed ID: 22500119
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
    Derom E, Brusselle GG, Joos GF.
    Int J Chron Obstruct Pulmon Dis; 2016 Jun 06; 11():3163-3177. PubMed ID: 28008243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.